UniQure and the U.S. Food and Drug Administration (FDA) reached alignment in July 2026 on an accelerated Biologics License Application pathway for AMT-130, a gene therapy for Huntington's disease. ^[1] William Blair initiated coverage of UniQure NV (NASDAQ: QURE) with an 'Outperform' rating, which served as the immediate trigger for the stock's 2.4% pre-market gain. ^[2] According to the article, analyst consensus on UniQure NV was 11 buy-equivalent ratings, 1 hold, and no sell recommendations. ^[3] President Trump hailed new deals struck with biopharma companies this week as part of his commitment to lowering drug costs. ^[4] STAT's John Wilkerson writes that the new agreements could even undercut the administration's own efforts to lower drug costs. ^[5] STAT's John Wilkerson writes that the new agreements struck with biopharma companies may not amount to much in terms of lowering costs. ^[6] UniQure stock traded below its 52-week high of $71.50 at the time of the article. ^[7] UniQure submitted applications to the FDA and the UK's MHRA seeking marketing approval for AMT-130, its treatment for Huntington's disease. ^[8]